"Finger Lakes Clinical Research, an Evolution Research Group Portfolio Company, is a clinical research facility in Rochester, New York, and is a wholly-owned medical research practice of Evolution Research Group (ERG) of New Providence, NJ. Under the direction of Dr. Sarah Atkinson, FLCR conducts clinical studies specializing in central nervous system (CNS) trials. These clinical trials encompass a broad range of illnesses including anxiety disorders, ADHD, major depression, bipolar (manic/depressive) illness and schizophrenia. In addition, we have conducted peripheral neuropathy (pain) studies and cancer pain trials."

During the past decade, Finger Lakes Clinical Research conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 59 clinical trials were completed, i.e. on average, 101.7% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 36 clinical trials were completed. i.e. 156.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Finger Lakes Clinical Research" #1 sponsor was "Sunovion" with 16 trials, followed by "Naurex, Inc, an affiliate of Allergan plc" with 8 trials sponsored, "Otsuka Pharmaceutical Development & Commercialization, Inc." with 7 trials sponsored, "Pfizer" with 7 trials sponsored and "Biohaven Pharmaceuticals, Inc." with 7 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Finger Lakes Clinical Research" #1 collaborator was "Astra Zeneca, Bristol-Myers Squibb" with 1 trials as a collaborator, "Neumora Therapeutics, Inc." with 1 trials as a collaborator, "Otsuka America Pharmaceutical" with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator and "Takeda" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Finger Lakes Clinical Research" are "Schizophrenia" (17 trials), "Major Depressive Disorder" (15 trials), "Depressive Disorder, Major" (12 trials), "Bipolar Disorder" (4 trials) and "Depression" (4 trials). Many other conditions were trialed in "Finger Lakes Clinical Research" in a lesser frequency.

Most popular intervention types in "Finger Lakes Clinical Research" are "Drug" (93 trials), "Other" (8 trials), "Biological" (5 trials), "Behavioral" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (55 trials), "Lurasidone" (8 trials), "Rapastinel" (6 trials), "ADT" (3 trials) and "OPC-34712" (3 trials). Other intervention names were less common.

The vast majority of trials in "Finger Lakes Clinical Research" are 97 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Finger Lakes Clinical Research". undefined are not yet recruiting, 13 are recruiting, 1 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 69 completed trials in Finger Lakes Clinical Research, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Finger Lakes Clinical Research, 1 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 59 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".